Physician profile
Tiffany Leyla Brett
NPI 1225890122
$6,926.50
in general payments reported to CMS, 2019-2025
23 companies · $2,626 in 2025
The $2,626 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $4,300 · 2025: $2,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,926.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,548.63 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $757.01 | 2024-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $622.05 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $566.10 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $560.62 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $520.85 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $440.52 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $346.33 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $297.48 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $222.77 | 2024 | Azstarys |
| Biogen, INC. | $154.39 | 2024-2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $135.95 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.52 | 2024-2025 | Trintellix |
| Noven Therapeutics, LLC | $116.16 | 2024 | Xelstrym |
| Indivior INC. | $110.72 | 2024-2025 | Sublocade, Perseris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $75.85 | 2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $60.79 | 2025 | Jornay Pm |
| Braeburn INC. | $51.48 | 2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $48.74 | 2025 | Cobenfy |
| Almatica Pharma LLC | $48.70 | 2024 | Loreev Xr |
| Tris Pharma INC | $47.47 | 2024-2025 | Dyanavel Xr |
| Owp Pharmaceuticals, INC. | $43.35 | 2024-2025 | Subvenite |
| Bausch Health US, LLC | $21.02 | 2025 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Brett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.